智通财经APP获悉，8月3日，绿叶制药(02186)宣布，其自主研发的1类创新药LY03021在中国开展的1期 临床研究已完成首例受试者入组。LY03021为去甲肾上腺素转运体(NET)/多巴胺转运体(DAT)抑制剂、 γ-氨基丁酸A受体正向变构调节剂(GABAAR PAM)，拟开发用于治疗抑郁症。 非临床研究显示，LY03021给药后24小时即显著改善模型动物的抑郁症状，且连续用药至为期21天的研 究结束时疗效稳定，表明LY03021兼具快速起效和疗效持久的优势。同时，该产品具有良好的安全性， 其NOAEL(未观察到毒副作用剂量)为有效剂量的50倍以上。 LY03021基于绿叶制药的新分子实体/新治疗实体技术平台(NCE/NTE)开发，为全新三靶点作用机制的抗 抑郁创新药。LY03021同时作用于去甲肾上腺素转运体(NET)、多巴胺转运体(DAT)和γ-氨基丁酸A受体 (GABAAR)。一方面，LY03021精准靶向突触内GABAA受体亚型α1β2γ2和突触外GABAA受体亚型 α4β3δ，具有更合理α1β2γ2受体亚型和α4β3δ受体亚型的作用强度比例，通过增强GABA对GABAA受体 激活，调节脑内谷氨 ...

8月3日，绿叶制药集团宣布，其自主研发的1类创新药LY03021在中国开展的I期临床研究已完成首例受 试者入组。LY03021为去甲肾上腺素转运体（NET）/多巴胺转运体（DAT）抑制剂、γ-氨基丁酸A受体 正向变构调节剂，拟用于治疗抑郁症。 ...

Group 1 - The company, Green Leaf Pharmaceutical (stock code: 02186), announced the issuance of 21,167,800 ordinary shares through the conversion of its 5.85% convertible bonds maturing in 2025, valued at 10 million USD [1] - The conversion price for the shares is set at HKD 3.672 per share [1]

绿叶制药(02186)发布公告，按每股兑换价3.672港元兑换由本公司发行的2025年到期的1000万美元5.85% 利率可转换债券而发行2116.78万股普通股股份。 ...

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02186 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的 ...

Group 1 - The top three companies with the highest short positions as of July 25 are WuXi AppTec (02359), CATL (03750), and Luye Pharma (02186), with short ratios of 23.32%, 16.32%, and 14.03% respectively [1][2] - The company with the largest absolute increase in short positions is Jinli Permanent Magnet (06680), with an increase of 3.23%, followed by Dongfang Electric (01072) and China Duty Free Group (01880) with increases of 2.55% and 2.52% respectively [1][2] - The companies with the largest absolute decrease in short positions include Dongfeng Motor Group (00489) with a decrease of -3.15%, followed by Jinxin Fertility (01951) and Ganfeng Lithium (01772) with decreases of -2.09% and -1.99% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include WuXi AppTec (02359) at 23.32%, CATL (03750) at 16.32%, and Luye Pharma (02186) at 14.03% [2] - The companies with the most significant increases in short ratios include Jinli Permanent Magnet (06680) from 1.45% to 4.68%, Dongfang Electric (01072) from 6.15% to 8.70%, and China Duty Free Group (01880) from 2.68% to 5.20% [2] - The companies with the most significant decreases in short ratios include Dongfeng Motor Group (00489) from 7.32% to 4.17%, Jinxin Fertility (01951) from 10.03% to 7.94%, and Ganfeng Lithium (01772) from 13.66% to 11.67% [3]

截至2024年年报，绿叶制药营业总收入60.61亿元、净利润4.72亿元。 本文源自：金融界 作者：行情君 8月1日，绿叶制药(02186)盘中下跌5.12%，截至13:27，报4.08元/股，成交2.17亿元。 绿叶制药集团有限公司主要在全球最大和增长最快的四个治疗领域（肿瘤科、中枢神经系统、心血管系 统及消化与代谢）进行创新药品的开发、生产、推广及销售，产品组合包括超过30种产品，覆盖全球80 个以上国家和地区。关键经营数据显示，2021年，公司产品销售覆盖全国30个省、自治区和直辖市，通 过约1000名销售和营销人员以及约1780家经销商网络，产品销往19330多家医院，同时在国际市场覆盖 80个国家或地区。 ...

7月30日，绿叶制药(02186)盘中下跌5.16%，截至13:49，报4.23元/股，成交2.59亿元。 绿叶制药集团有限公司主要在全球最大和增长最快的四个治疗领域（肿瘤科、中枢神经系统、心血管系 统及消化与代谢）进行创新药品的开发、生产、推广及销售，产品组合包括超过30种产品，覆盖全球80 个以上国家和地区。关键经营数据显示，2021年，公司产品销售覆盖全国30个省、自治区和直辖市，通 过约1000名销售和营销人员以及约1780家经销商网络，产品销往19330多家医院，同时在国际市场覆盖 80个国家或地区。 本文源自：金融界 作者：行情君 截至2024年年报，绿叶制药营业总收入60.61亿元、净利润4.72亿元。 ...

Group 1 - The top three companies with the highest short positions are WuXi AppTec (02359), CATL (03750), and COSCO Shipping Holdings (01919), with short ratios of 23.99%, 17.39%, and 14.14% respectively [1][2] - The companies with the largest increase in short positions are Giant Biogene (02367), WuXi AppTec (02359), and Henderson Land Development (00012), with increases of 2.05%, 1.43%, and 1.41% respectively [1][2] - The companies with the largest decrease in short positions are SF Holding (06936), Far East Horizon (03360), and Jiumaojiu International Holdings (09922), with decreases of -1.94%, -1.22%, and -1.18% respectively [1][3] Group 2 - The top ten companies with the highest short ratios include Ganfeng Lithium (01772) at 13.09%, Xiexin Technology (03800) at 12.57%, and Shandong Gold (01787) at 12.35% [2] - The companies with the largest increase in short ratios also include Fuyou Glass (06865) at 12.07% and Tigermed (03347) at 9.81% [2] - The companies with the largest decrease in short ratios include Vanke Enterprise (02202) at 11.38% and Green Leaf Pharmaceutical (02186) at 11.96% [3][4]

Market Overview - Hong Kong stocks experienced a pullback after an initial rise, with the Hang Seng Index closing down 0.29% at 24,517.76 points and a total trading volume of 258.95 billion HKD [1] - The Hang Seng China Enterprises Index fell 0.18% to 8,861.39 points, while the Hang Seng Tech Index decreased by 0.24% to 5,418.4 points [1] - Shenwan Hongyuan remains optimistic about investment opportunities in Hong Kong and A-share markets, predicting that Hong Kong will play a crucial role in the restructuring of the global financial order [1] Blue Chip Performance - Anta Sports (02020) led blue-chip stocks, rising 2.28% to 91.85 HKD, contributing 4.55 points to the Hang Seng Index [2] - Other notable performers included Kuaishou-W (01024) up 2.13% and Trip.com Group-S (09961) up 1.59%, while Shenzhou International (02313) and Zhongsheng Holdings (00881) saw declines of 2.75% and 2.67%, respectively [2] Sector Highlights - Large tech stocks showed mixed results, with Kuaishou rising over 2% and Baidu nearly 1%, while Tencent fell 0.19% [3] - The humanoid robot sector is gaining traction, with Shengye rising nearly 15% following positive developments [3] - The innovative drug sector remains active, with Lijun Pharmaceutical rising 13% amid ongoing interest in new drug procurement [4][5] Innovative Drug Sector - The 11th batch of national drug procurement has started, focusing on mature "old drugs" while excluding innovative drugs [5] - Analysts believe that the current innovative drug market is driven by value reassessment, with domestic investors increasing their positions through Hong Kong Stock Connect [5] Stablecoin Activity - China San San Media (08087) surged 72.73% after announcing plans to apply for a stablecoin license in Hong Kong, which will officially take effect on August 1 [6] - The global regulatory framework for stablecoins is expected to lead to significant industry growth [6] New Consumption Trends - New consumption stocks showed varied performance, with Guoquan (02517) up 7.29% and Hu Shang Ayi (02589) up 1.99%, while Gu Ming (01364) fell 4.26% [7] - Guoquan expects a net profit of approximately 180 to 210 million RMB for the first half of 2025, representing a year-on-year increase of 111% to 146% [7] Notable Stock Movements - Weiyali (00854) saw a dramatic increase of 288.34% after resuming trading, reaching a peak of 33.2 HKD [8] - Chongqing Machinery (02722) rose 14.06% following news of NVIDIA resuming sales of its H20 chip in China [9] - Jiufang Zhitu Holdings (09636) increased by 10.06% as it plans to issue shares for strategic investments [10] - Quzhi Group (00917) fell 12.06% after announcing a share placement at a discount to its market price [11]